The effectiveness and safety of Kami Guibi-tang for mild cognitive impairment: study protocol of a pilot, randomized, placebo-controlled, double-blind trial

BACKGROUND: Mild cognitive impairment (MCI) is an intermediate phase between normal aging and dementia. Since a majority of amnestic MCI (aMCI) cases progress to Alzheimer’s disease (AD), it is considered the prodromal stage of AD and, therefore, a treatment target for the prevention of further cogn...

Description complète

Détails bibliographiques
Auteurs principaux: Shin, Hee-Yeon, Kim, Jeong-Hwa, Jahng, Geon-Ho, Jung, Woo-Sang, Park, Seong-Uk, Ko, Chang-Nam, Park, Jung-Mi
Format: Online Article Texte
Langue:English
Publié: BioMed Central 2019
Sujets:
Study Protocol
Accès en ligne:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647292/
https://www.ncbi.nlm.nih.gov/pubmed/31331367
http://dx.doi.org/10.1186/s13063-019-3567-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647292/
https://www.ncbi.nlm.nih.gov/pubmed/31331367
http://dx.doi.org/10.1186/s13063-019-3567-1

Documents similaires